February 26, 2021 5:53pm

I am able to walk the talk of data and science to provide better sector investment, updates and review

News: J&J’s (JNJ) is unanimously passed advisory panel review and emergency use authorization should be approved – TOMMORROW!

Pre-open indication results: 3 HITs and 5 MISS

The week in review …

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

The Dow closed DOWN -469.54 points (-1.50%); the S&P closed DOWN -18.19 points (-0.47%) while the Nasdaq closed UP +72.91 points (+0.56%)

 

Henry’omics:

The Dow and S&P are down as the Nasdaq shakes it off …

This week, the S&P is down -1.5%, with the Dow at -0.9% and the Nasdaq lost -4%; while this month, the S&P 500 is up +4% with the Dow rising +3.5 % while the Nasdaq is up +1.9%.

 

Data Docket: the personal consumption expenditures price index indicated subdued inflation in January. The PCE index, which the Federal Reserve watches closely, rose 0.3% for the month, slightly ahead of the 0.2% expectation but was up just 1.5% year over year, matching estimates.

 

RegMed Investors’ (RMi) pre-open: “momentum and resistance, the cause and causation of the month’s last session. The key to this market’s movement is the U.S. Senates’ ability to approve the fiscal aid/stimulus “bill” without the excess of “pork” inclusions while markets are churned by a sudden spike in bond yields that sent some investors fleeing” … https://www.regmedinvestors.com/articles/11788

 

Pre-open indication results:  3 HITs < SELL: Biostage (BSTG -$0.15 with 959 shares traded); Falling Knives: Caladrius Biosciences (CLBS -$0.02), Editas Medicine (EDIT -$0.90) and 5 MISS: MiMedx (MDXG +$0.16), Sage Therapeutics (SAGE +$1.55) <CRISPR Therapeutics (CRSP +$1.59).  Intellia Therapeutics (NTLA +$2.99), Ultragenyx (RARE +$5.29)>  

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions 

  • Friday opened negative at 4/27, 3 flat and 1 acquired, flipped positive at the mid-day to 18/15, 1 flat and 1 acquired, closing positive at 18/15, 1 flat and 1 acquired;
  • Thursday opened negative at 13/19, 2 flat and 1 acquired, stayed negative at the mid-day to 4/29,13 flat and 1 acquired, closing negative at 3/30, 1 flat and 1 acquired;
  • Wednesday opened positive at 20/12, 2 flat and 1 acquired, stayed positive at the mid-day to 31/1, 3 flat and 1 acquired, closing positive at 7/25, 2 flats and 1 acquired;
  • Tuesday opened negative at 4/30 and 1 acquired, stayed negative at the mid-day to 6/28 and 1 acquired, closing negative at 8/26 and 1 acquired;
  • Monday opened negative at 12/22 and 1 acquired, stayed negative at the mid-day to 10/24 and 1 acquired, closing negative at 7/27 and 1 acquired;

 

There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

  • Ultragenyx (RARE), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), bluebird bio (BLUE), Sage Therapeutics (SAGE) to name 5 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS), Global Blood Therapeutics (GBT), Editas Medicine (EDIT), to name 5 of the 15 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 6 of the 18-upside having higher than the 3-month average volume with the increased volume of 5 of 15-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 18-upside were +0.48% (PSTI) to +10.60% (BLUE) while the 15-downside ranges from -0.42% (VSTM) to -8.99% (VYGR);

 

Friday’s (10 of 18) incline

  • Ultragenyx (RARE +$5.29 after Thursday’s -$6.48, Wednesday’s +$2.51, Tuesday’s -$4.47 and Monday’s -$3.45);
  • Fate Therapeutics (FATE +$3.45 after Thursday’s -$9.00, Wednesday’s -$0.21, Tuesday’s -$5.48 and Monday’s -$9.22);
  • Intellia Therapeutics (NTLA +$2.99 after Thursday’s -$6.25);
  • Sage Therapeutics (SAGE +$1.55);
  • Alnylam Pharmaceuticals (ALNY +$1.51 after Thursday’s -$5.00, Wednesday’s -$1.62, Tuesday’s +$5.14 and Monday’s -$4.73);
  • Regenxbio (RGNX +$0.93);
  • Cellectis SA (CLLS +$0.86);
  • Vericel (VCEL +$0.71 after Thursday’s -$1.88, Wednesday’s +$2.08, Tuesday’s -$1.07 and Monday’s -$2.96);
  • AxoGen (AXGN +$0.57);

Friday’s (10 of 15) decliners:

  • ReNeuron (RENE.L -$2.00 after Thursday’s +$0.50);
  • CRISPR Therapeutics (CRSP -$1.59 after Thursday’s -$6.24, Wednesday’s -$1.78, Tuesday’s -$2.59 and Monday’s -$10.42);
  • Ionis Pharmaceuticals (IONS -$1.01 after Thursday’s -$2.80);
  • Global Blood Therapeutics (GBT -$0.90 after Thursday’s -$5.69 and Wednesday’s +$1.16);
  • Editas Medicine (EDIT -$0.90 after Thursday’s -$4.94, Wednesday’s +$0.56, Tuesday’s -$3.26 and Monday’s -$4.07);
  • Voyager therapeutics (VYGR -$0.56);
  • uniQure NV (QURE -$0.30);
  • Applied Genetic Technologies (AGTC -$0.22)
  • Biostage (BSTG -$0.15 after Thursday’s -$0.00, Wednesday’s -$0.00, Tuesday’s -$0.20 and Monday’s +0.145);
  • Caladrius Biosciences (CLBS -$0.13);

Closing 1 – Mesoblast (MESO), and 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19 infections:

  • A key FDA advisory panel will review and vote on Johnson & Johnson’s (JNJ) single-shot Covid-19 vaccine TONIGHT, potentially paving the way for an emergency use authorization – TOMMORROW!
  • If authorized, JNJ’s shot would be the third (3rd) to be made available in the U.S. and would be distributed through a comparatively simple supply chain. The one-dose regimen eliminates the need to track return visits, and the drug can be stored at less extreme temperatures than vaccines made by Pfizer (PFE) and Modern (MRNA).
  • The influx of supply and simplified logistics would likely mean an immediate boost to national vaccination rates when the vaccine hits the market as early as next week.

Infection cases <Million>: never to forget …

  • Friday 28.46 M cases,
  • Friday’s death rate totaled 509,734 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -0.14% and XBI closed up +0.76%
  • Thursday, the IBB closed down -2.65% and XBI closed down -4.06%
  • Wednesday, the IBB closed up +0.97% and XBI closed up +1.51%
  • Tuesday, the IBB closed down -1.40% and XBI closed down -2.24%
  • Monday, the IBB closed down -2.51% and XBI closed down -3%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.94 points or -3.25% at 27.95
  • Thursday was up +7.55 points or +35.38% at 28.89
  • Wednesday was down -1.77 points or -7.66% at 21.34
  • Tuesday was up +0.34 points or +1.45% at 23.11
  • Monday was up +1.40 points or +4.35% at 23.45

Upside volume: low

  • Friday: 6 out of the 18-upside had higher than the 3-month average volume;
  • Thursday: 1 out of the 3-upside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 25-upside had higher than the 3-month average volume;
  • Tuesday: 4 out of the 8-upside had higher than the 3-month average volume;
  • Monday: 2 out of the 7-upside had higher than the 3-month average volume;

Downside volume: low

  • Friday: 5 out of the 15-downside had higher than the 3-month average volume;
  • Thursday: 9 out of the 30-downside had higher than the 3-month average volume;
  • Wednesday: 2 out of the 7-downside had higher than the 3-month average volume;
  • Tuesday: 15 out of the 26-downside had higher than the 3-month average volume;
  • Monday: 7 out of the 27-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Friday’s percentage (%) of the 18-upside were +0.48% (PSTI) to +10.60% (BLUE) while the 15-downside ranges from -0.42% (VSTM) to -8.99% (VYGR);
  • Thursday’s percentage (%) of the 3-upside were +0.44% (RENE.L) to +8.49% (BLUE) while the 30-downside ranges from -1.25% (QURE) to -13.03% (SLDB);
  • Wednesday’s percentage (%) of the 25-upside were +0.24% (NTLA) to +13.37% (CLBS) while the 7-downside ranges from -0.22% (FATE) to -5.74% (MESO);
  • Tuesday’s percentage (%) of the 8-upside were +0.20% (IONS) to +41.78% (SLDB) while the 26-downside ranges from -0.33% (QURE) to -16.14% (CLBS);
  • Monday’s percentage (%) of the 7-upside were +0.22% (QURE) to +7.82% (BSTG – “pumped”) while the 27-downside ranges from -0.39% (MESO) to -33.62% (BCLI);

 

February, the 2nd month of Q1 … the final week:

Friday closed negative with 18 advancers, 15 decliners, 1 flat and 1 acquired

Thursday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Wednesday closed positive with 25 advancers, 7 decliners, 2 flat and 1 acquired

Tuesday closed negative with 8 advancers, 26 decliners and 1 acquired

Monday (2/22) closed negative with 7 advancers, 27 decliners and 1 acquired

Friday closed positive with 24 advancers, 9 decliners, 1 flat and 1 acquired

Thursday closed negative with 2 advancers, 32 decliners and 1 acquired

Wednesday closed negative with 11 advancers, 23 decliners and 1 acquired

Tuesday closed negative with 14 advancers, 20 decliners and 1 acquired

Monday (2/15) was a market holiday

Friday closed negative with 14 advancers, 19 decliners, 1 flat and 1 acquired

Thursday closed positive with 13 advancers, 21 decliners and 1 acquired

Wednesday closed negative with 8 advancers, 25 decliners, 1 flat and 1 acquired

Tuesday closed negative with 11 advancers, 23 decliners and 1 acquired

Monday (2/8) closed positive with 27 advancers, 7 decliners, 1 flat and 1 acquired

Friday closed positive with 28 advancers, 6 decliners and 1 acquired

Thursday closed positive with 27 advancers, 7 decliners and 1 acquired

Wednesday closed positive with 17 advancers, 16 decliners, 1 flat and 1 acquired

Tuesday closed positive with 25 advancers, 7 decliners, 2 flats and 1 acquired

Monday (2/1) closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: the second month of Q1 is over … and has been another “mirror” looks to it…

  • February: 10 positive, 9 negative closes and 1 holiday to date
  • January: 10 positive, 9 negative closes and 1 holiday

AN ISSUE FOR ME IS many investors whether “tourists” or not are taking profits and not necessarily reinvesting those monies!

There is always a shift going-on however, these last two (2) months continues to leave me … QUESTIONING staying longer than a WEEK as I have said recently - my horizon on Monday is to meet on Friday.

  • Especially after the last three (3) weeks.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.